In a patient population with minimum exclusion criteria and high adherence to dual antiplatelet therapy , biodegradable polymer sirolimus-eluting stents were non-inferior to durable polymer everolimus-eluting stents for the combined safety and efficacy outcome target lesion failure at 12 months .